Compare SGA & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGA | ACET |
|---|---|---|
| Founded | 1986 | 1947 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 69.6M |
| IPO Year | 1994 | 2017 |
| Metric | SGA | ACET |
|---|---|---|
| Price | $11.12 | $6.94 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $56.00 |
| AVG Volume (30 Days) | 8.4K | ★ 111.8K |
| Earning Date | 03-12-2026 | 03-12-2026 |
| Dividend Yield | ★ 8.94% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $10.68 | $0.45 |
| 52 Week High | $14.27 | $9.05 |
| Indicator | SGA | ACET |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 45.55 |
| Support Level | $10.68 | $6.54 |
| Resistance Level | $12.60 | $8.34 |
| Average True Range (ATR) | 0.22 | 0.44 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 23.63 | 17.94 |
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.